Selecting the most promising pre-clinical projects to become ready for clinical trials

Our therapeutic focus prioritises cancer, related conditions and women’s health. Our pipeline is enriched by robust partnerships with academia and industry, fuelled by our intellectual and financial resources. Our development process varies for each of our molecules and is specifically structured to minimise risk and maximise the chances of successful clinical development and approval for clinical trials. To view the full breakdown of our pipeline and the current projects we have, click here.

We identify, incubate and accelerate innovations that focus on the needs of those who matter most – patients. With a sense of urgency and determination, we select molecules with the highest potential to improve patient lives throughout treatment.

We are continuously working with our partners to think of new and innovative ways to focus on our therapeutic areas. our latest project, Cytolytix, is a partially-owned ValiRx subsidiary, which signed an IP license agreement with King's College London. This partnership has been established to progress the triple negative breast cancer project, CLX001, through preclinical development to a stage of readiness for clinical trials. Read more about the Cytolytix project, and it's current progress within our project pipeline here.

We develop treatments derived from diverse and disruptive innovations that have the potential to progress rapidly upstream and deliver value to all of our stakeholders. Our model and industry expertise enables us to accelerate the translation of promising new drug candidates to early clinical studies. Strategic partnering to co-develop and fund later-stage clinical trials, allows ValiRx to continue to build a risk-balanced pipeline of novel projects.

Read more about our key areas of focus here.

Find – Focus –Transform – Grow

Our core strategy can be broken down into four areas:

Find – We identify and select innovations which fit our therapeutic interests, expertise and strategic model.

Focus – We devote intellectual and financial resources to deliver a risk-balanced pipeline of projects that are investor and industry ready.

Transform – Starting with the end in mind, we collaborate with world-leading innovators to enhance and accelerate the translation of great science into effective treatments.

Grow – Our strategy includes building a portfolio of independent entities with a common support framework and a shared vision. Dynamic joint ventures and end-focused partnerships will progress each entity to commercialisation and deliver maximum value.